On October 22, 2024, Steven Collis, the Executive Chairman of Cencora Inc (COR, Financial), sold 21,509 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 285,088 shares of Cencora Inc.
Cencora Inc, formerly known as AmerisourceBergen, is a global healthcare company focused on improving product access, increasing supply chain efficiency, and enhancing patient care. The company operates through various segments, including Pharmaceutical Distribution and Strategic Global Sourcing.
Over the past year, Steven Collis has sold a total of 200,430 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed within the company, where there have been 26 insider sells and only 1 insider buy over the past year.
On the valuation front, shares of Cencora Inc were trading at $235.8 on the day of the transaction. The company has a market cap of approximately $45.97 billion. The price-earnings ratio of Cencora Inc stands at 25.46, which is above both the industry median of 19.96 and the company's historical median.
The GF Value of Cencora Inc is estimated at $213.23, suggesting that the stock is Fairly Valued with a price-to-GF-Value ratio of 1.11.
The GF Value is calculated considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sell event and the current valuation metrics provide investors with updated data points to consider in their analysis of Cencora Inc's stock performance and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
